Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
University of Florida
University of California, San Francisco
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Stanford University
Baylor College of Medicine
St. Jude Children's Research Hospital
Medical College of Wisconsin
Seattle Children's Hospital
Seattle Children's Hospital
Dana-Farber Cancer Institute
Seattle Children's Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Baylor College of Medicine
Nationwide Children's Hospital
Baylor College of Medicine
The University of Texas Health Science Center, Houston
Foghorn Therapeutics Inc.
Taipei Medical University
Australian & New Zealand Children's Haematology/Oncology Group
Ipsen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)